KIYATEC, Inc. today announced plans to expand operations in Greenville County. The $5 million investment will create 91 new jobs.
Founded in 2005, KIYATEC, Inc. is a commercial stage cancer diagnostics company born from technology developed at Clemson University, creating transformative solutions for cancer patients using functional precision oncology. KIYATEC, Inc. recently launched its first commercial assay 3D Predict™ Glioma for use in glioblastoma (commonly known as GBM) and other brain cancer patient care.
The company established its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory and began clinical studies in 2015, developing proprietary “ex vivo” 3D cell culture technology platforms to accurately model and predict patient-specific response to approved and investigational cancer drugs targeting a spectrum of solid tumors.
“Securing testing capacity to bring our testing to thousands, then tens of thousands of cancer patients is a business decision that positions us to win and increases our competitive advantage. As a Greenville-based life sciences company, KIYATEC benefits from all this area has to offer including its highly-educated labor force, excellent quality of life for our employees, competitive cost profile and business-friendly environment,” said KIYATEC, Inc. Chief Executive Officer Matt Gevaert, Ph.D.
Located at 2 N. Main Street in Greenville, KIYATEC, Inc.’s downtown facility will allow the company to expand its existing clinical testing operations and drug development services which are co-located with the Cancer Institute at nearby Prisma Health’s Memorial Campus. This new facility will be the anchor tenant of the city of Greenville’s new Innovation District.
The new offices are expected to be operational by January 2022 and the CLIA-certified laboratory by April 2022. Individuals interested in joining the KIYATEC, Inc. team should visit the company’s website.